Patents by Inventor Nicholas Chi-Kwan Ling
Nicholas Chi-Kwan Ling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11846642Abstract: The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble ?4?7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.Type: GrantFiled: August 9, 2019Date of Patent: December 19, 2023Assignee: Prometheus Laboratories Inc.Inventors: Jared Salbato, Stefan Westin, Nicholas Chi-Kwan Ling, Anjali Jain, Sharat Singh
-
Publication number: 20200088749Abstract: The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble ?4?7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.Type: ApplicationFiled: August 9, 2019Publication date: March 19, 2020Inventors: Jared Salbato, Stefan Westin, Nicholas Chi-Kwan Ling, Anjali Jain, Sharat Singh
-
Patent number: 10422807Abstract: The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble ?4?7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.Type: GrantFiled: May 23, 2017Date of Patent: September 24, 2019Assignee: PRECISION IBD, INC.Inventors: Jared Salbato, Stefan Westin, Nicholas Chi-Kwan Ling, Anjali Jain, Sharat Singh
-
Patent number: 10184940Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether a sample from an individual is an IBS sample or a healthy control sample using a statistical algorithm. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.Type: GrantFiled: March 30, 2015Date of Patent: January 22, 2019Assignee: Nestec S.A.Inventors: Sharat Singh, Nicholas Chi-Kwan Ling, Shui-Long Wang, Fred Princen, Stefan Westin, Steven Lockton
-
Patent number: 9884918Abstract: The present invention provides cyclic peptides comprising a dimer of peptides, each peptide comprising a sequence corresponding to the HER2 splice variant HER2Delta16, wherein the cyclic peptide is cyclized via a disulfide bond between the peptides and via an amino acid linking the peptides. The invention also provides methods of making antibodies that specifically bind to HER2Delta16 homodimers using said cyclic peptides.Type: GrantFiled: March 21, 2017Date of Patent: February 6, 2018Assignee: Nestec S.A.Inventor: Nicholas Chi-Kwan Ling
-
Publication number: 20170328923Abstract: The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble ?4?7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.Type: ApplicationFiled: May 23, 2017Publication date: November 16, 2017Applicant: Nestec S.A.Inventors: Jared Salbato, Stefan Westin, Nicholas Chi-Kwan Ling, Anjali Jain, Sharat Singh
-
Publication number: 20170298144Abstract: The present invention provides cyclic peptides comprising a dimer of peptides, each peptide comprising a sequence corresponding to the HER2 splice variant HER2Delta16, wherein the cyclic peptide is cyclized via a disulfide bond between the peptides and via an amino acid linking the peptides. The invention also provides methods of making antibodies that specifically bind to HER2Delta16 homodimers using said cyclic peptides.Type: ApplicationFiled: March 21, 2017Publication date: October 19, 2017Applicant: NESTEC S.A.Inventor: NICHOLAS CHI-KWAN LING
-
Patent number: 9630993Abstract: The present invention provides cyclic peptides comprising a dimer of peptides, each peptide comprising a sequence corresponding to the HER2 splice variant HER2Delta16, wherein the cyclic peptide is cyclized via a disulfide bond between the peptides and via an amino acid linking the peptides. The invention also provides methods of making antibodies that specifically bind to HER2Delta16 homodimers using said cyclic peptides.Type: GrantFiled: May 14, 2015Date of Patent: April 25, 2017Assignee: NESTEC S.A.Inventor: Nicholas Chi-Kwan Ling
-
Publication number: 20150346200Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether a sample from an individual is an IBS sample or a healthy control sample using a statistical algorithm. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.Type: ApplicationFiled: March 30, 2015Publication date: December 3, 2015Applicant: NESTEC S.A.Inventors: SHARAT SINGH, Nicholas Chi-Kwan Ling, Shui-Long Wang, Fred Princen, Stefan Westin, Steven Lockton
-
Publication number: 20150315291Abstract: The present invention provides cyclic peptides comprising a dimer of peptides, each peptide comprising a sequence corresponding to the HER2 splice variant HER2Delta16, wherein the cyclic peptide is cyclized via a disulfide bond between the peptides and via an amino acid linking the peptides. The invention also provides methods of making antibodies that specifically bind to HER2Delta16 homodimers using said cyclic peptides.Type: ApplicationFiled: May 14, 2015Publication date: November 5, 2015Inventor: Nicholas Chi-Kwan Ling
-
Patent number: 9062096Abstract: The present invention provides cyclic peptides comprising a dimer of peptides, each peptide comprising a sequence corresponding to the HER2 splice variant HER2Delta16, wherein the cyclic peptide is cyclized via a disulfide bond between the peptides and via an amino acid linking the peptides. The invention also provides methods of making antibodies that specifically bind to HER2Delta16 homodimers using said cyclic peptides.Type: GrantFiled: May 23, 2013Date of Patent: June 23, 2015Assignee: NESTEC S.A.Inventor: Nicholas Chi-Kwan Ling
-
Publication number: 20140170683Abstract: The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided.Type: ApplicationFiled: July 26, 2013Publication date: June 19, 2014Applicant: NESTEC S.A.Inventors: Nicholas Chi-Kwan Ling, Shui Long Wang, Dunrui Wang, Sharat Singh
-
Publication number: 20130317195Abstract: The present invention provides cyclic peptides comprising a dimer of peptides, each peptide comprising a sequence corresponding to the HER2 splice variant HER2Delta16, wherein the cyclic peptide is cyclized via a disulfide bond between the peptides and via an amino acid linking the peptides. The invention also provides methods of making antibodies that specifically bind to HER2Delta16 homodimers using said cyclic peptides.Type: ApplicationFiled: May 23, 2013Publication date: November 28, 2013Inventor: Nicholas Chi-Kwan Ling
-
Patent number: 8519096Abstract: The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided.Type: GrantFiled: September 21, 2011Date of Patent: August 27, 2013Assignee: Nestec S.A.Inventors: Nicholas Chi-Kwan Ling, Shui Long Wang, Dunrui Wang, Sharat Singh
-
Patent number: 8445215Abstract: The present invention provides devices and methods for aiding in the diagnosis of Crohn's disease. The devices and methods accurately identify whether a sample from an individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof such as Crohn's disease (CD). The present invention is useful for determining whether a sample from an individual is an IBD sample, or differentiating between CD and ulcerative colitis (UC). Thus, the present invention provides an accurate diagnostic prediction of IBD or a clinical subtype thereof and prognostic information useful for guiding treatment decisions.Type: GrantFiled: July 25, 2011Date of Patent: May 21, 2013Assignee: Nestec S.A.Inventors: Shui-Long Wang, Nicholas Chi-Kwan Ling, Sharat Singh
-
Publication number: 20120295280Abstract: The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided.Type: ApplicationFiled: September 21, 2011Publication date: November 22, 2012Applicant: Prometheus Laboratories Inc.Inventors: Nicholas Chi-Kwan Ling, Shui Long Wang, Dunrui Wang, Sharat Singh